Ibandronic Acid and Calcium Orotate: Brands, Price & Uses in Bangladesh

Ibandronic Acid and Calcium Orotate is a fixed-dose combination of a nitrogen-containing bisphosphonate (ibandronic acid) and a calcium salt (calcium orotate), used mainly in the management of osteoporosis.

Established / Guideline-Supported Uses

• Treatment of postmenopausal osteoporosis – to reduce the risk of vertebral fractures. This is the core, well-established indication for the ibandronic acid component; the calcium orotate component is included to help meet the recommended daily calcium intake needed to support bisphosphonate therapy and healthy bone mineralization.
• Prevention of postmenopausal osteoporosis in women at increased risk of bone loss (e.g., early menopause, low bone mineral density on screening).

Adjunct / Combination-Dependent Uses

• As part of a broader osteoporosis management plan that also includes weight-bearing exercise, adequate vitamin D intake, and fall-prevention measures — Ibandronic Acid and Calcium Orotate is not a substitute for these lifestyle measures.
• Used to help correct or prevent calcium deficiency in patients on long-term bisphosphonate therapy, where the calcium orotate component supplements dietary calcium intake.

Off-Label Use

Some clinicians use ibandronic acid off-label for glucocorticoid-induced osteoporosis or osteoporosis in men, but Ibandronic Acid and Calcium Orotate as a fixed combination product does not have a formally labeled indication for these uses; such use should only be under specialist supervision.

Adult Dose

Pediatric Dose

Not established. Ibandronic Acid and Calcium Orotate is not indicated for use in children or adolescents; safety and efficacy in this population have not been demonstrated.

Renal Impairment

No dose adjustment is generally required in mild-to-moderate renal impairment. Ibandronic Acid and Calcium Orotate should not be used in patients with severe renal impairment (creatinine clearance below approximately 30–35 mL/min), as bisphosphonate clearance is reduced and toxicity risk increases (see Contraindications).

Hepatic Impairment

No specific dose adjustment is established; use with routine clinical caution as no dedicated studies exist for the ibandronic acid component in hepatic impairment.

Administration Instructions

Take Ibandronic Acid and Calcium Orotate first thing in the morning, at least 30–60 minutes before the first food, drink (other than plain water), or other oral medication of the day. Swallow the tablet whole with a full glass (180–240 mL) of plain water while sitting or standing upright; do not lie down for at least 60 minutes after taking the dose. Do not chew, crush, or suck the tablet.

Side effects reported with Ibandronic Acid and Calcium Orotate include:

Common

• Musculoskeletal pain (back pain, myalgia, arthralgia)
• Gastrointestinal upset (dyspepsia, nausea, diarrhea, constipation, abdominal pain)
• Headache
• Flu-like symptoms (fever, chills, myalgia) — more common after initial doses, especially with intravenous bisphosphonate formulations

Less Common / Serious (seek medical attention)

• Esophagitis, esophageal ulceration, or esophageal irritation (chest pain, difficulty or pain on swallowing, new/worsening heartburn)
• Symptoms of hypocalcemia (muscle cramps, spasms, numbness/tingling around the mouth or in fingers)
• Osteonecrosis of the jaw (jaw pain, swelling, non-healing sores in the mouth) — rare, see Precautions and Warnings
• Atypical femur fractures (new or unusual thigh/groin pain) — rare, see Precautions and Warnings
• Severe allergic reactions (rash, swelling, difficulty breathing)